CRISPR Therapeutics showed that its new gene editing treatment cut lipid levels in patients with high triglycerides.

Nov 10, 2026, 1:51 PM ETTrialRead the original at Benzinga

Good for CRSP

CRISPR Therapeutics said CTX310 cut triglycerides by 63% on average, and no serious treatment-related problems were reported. Only 10 patients took part, so larger studies must confirm the benefit.

CRSP · CRISPR Therapeutics AG

AI read · Good for CRSP

The AI's read

The results make CTX310 look promising for people with very high triglyceride levels. The study also reported no serious treatment-related problems. But it included only 10 patients, so larger studies must confirm the benefits and safety.

Get alerts for CRSP

Follow CRISPR Therapeutics AG (CRSP) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CRSP

Free on the App Store and Google Play, or on the web.